Baker McKenzie was invited again to serve as the global editor of the Chambers Life Sciences Practice Guide, which features 19 jurisdictions. This is the sixth consecutive year the Firm has provided its expertise and insight to the annual guide, which offers commentary on a wide range of legal and business issues in major healthcare and life sciences markets.
The reader may welcome the fact that, against a general trend to have increasingly more narrowly defined international guides, the legal content of this publication encompasses two related yet very different sectors of life sciences: medicines and medical devices. This makes it the most complete publication right now, covering all the main aspects of the life cycle of medical products.
Chair of the Global Healthcare & Life Sciences Industry Group Vanina Caniza, as well as partners Christian López-Silva, Roel Meers and Elisabeth White, co-authored the global introduction of the guide. The introduction discusses the emerging trends and strategic imperatives driving the highly regulated life sciences sector, including the rise of digital health solutions, licensing and collaboration agreements and tech M&A. It also features insights pertaining to supply chains, emerging ESG considerations, medical cannabis, IP risks and more.
The guide provides the latest developments and updates to in-house counsel and business executives on: regulations and compliance; clinical trials; marketing, manufacturing and distribution of pharmaceuticals and medical devices; pricing; digital health; patents; and COVID-19.
At the same time, the Firm also authored national chapters in four jurisdictions:
Australia co-authored by Partners Elisabeth White, Helen Macpherson and Senior Associate Chantal Savage
